MedTrace Logo

Glecaprevir/Pibrentasvir Real-world Study in China

NCT03941821 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2019-05-08

No results posted yet for this study

Summary

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

Glecaprevir/Pibrentasvir

Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Qin Ning, PHD,MD · Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College HUST

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2021-06-30
Completion
2022-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03941821 on ClinicalTrials.gov